Oppenheimer & Co. Inc. Takes $209,000 Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Oppenheimer & Co. Inc. purchased a new stake in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 17,885 shares of the company’s stock, valued at approximately $209,000.

A number of other institutional investors have also recently made changes to their positions in the company. Atria Investments Inc boosted its holdings in Intellia Therapeutics by 24.3% in the third quarter. Atria Investments Inc now owns 23,099 shares of the company’s stock worth $475,000 after purchasing an additional 4,511 shares during the last quarter. Privium Fund Management B.V. purchased a new stake in Intellia Therapeutics in the third quarter worth approximately $253,000. Axxcess Wealth Management LLC boosted its holdings in Intellia Therapeutics by 5.4% in the third quarter. Axxcess Wealth Management LLC now owns 20,215 shares of the company’s stock worth $415,000 after purchasing an additional 1,044 shares during the last quarter. KBC Group NV boosted its holdings in Intellia Therapeutics by 37.3% in the third quarter. KBC Group NV now owns 3,753 shares of the company’s stock worth $77,000 after purchasing an additional 1,020 shares during the last quarter. Finally, Curi RMB Capital LLC boosted its holdings in Intellia Therapeutics by 13.5% in the third quarter. Curi RMB Capital LLC now owns 39,187 shares of the company’s stock worth $805,000 after purchasing an additional 4,662 shares during the last quarter. Hedge funds and other institutional investors own 88.77% of the company’s stock.

Insider Activity

In other Intellia Therapeutics news, CEO John M. Leonard sold 26,807 shares of Intellia Therapeutics stock in a transaction on Friday, January 3rd. The shares were sold at an average price of $12.18, for a total value of $326,509.26. Following the sale, the chief executive officer now directly owns 941,115 shares in the company, valued at approximately $11,462,780.70. The trade was a 2.77 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders have sold 29,000 shares of company stock worth $352,551 in the last three months. Company insiders own 3.20% of the company’s stock.

Intellia Therapeutics Price Performance

Shares of NTLA stock opened at $10.35 on Monday. The company has a market capitalization of $1.07 billion, a price-to-earnings ratio of -1.90 and a beta of 1.97. Intellia Therapeutics, Inc. has a one year low of $8.30 and a one year high of $32.00. The company’s fifty day moving average price is $10.61 and its 200-day moving average price is $15.07.

Wall Street Analysts Forecast Growth

NTLA has been the topic of several research reports. Oppenheimer dropped their target price on shares of Intellia Therapeutics from $60.00 to $40.00 and set an “outperform” rating on the stock in a report on Monday, January 13th. Barclays decreased their price target on shares of Intellia Therapeutics from $55.00 to $26.00 and set an “overweight” rating on the stock in a research report on Friday, February 28th. Truist Financial decreased their price target on shares of Intellia Therapeutics from $90.00 to $50.00 and set a “buy” rating on the stock in a research report on Tuesday, March 4th. StockNews.com upgraded shares of Intellia Therapeutics to a “sell” rating in a research report on Monday, March 3rd. Finally, Wells Fargo & Company decreased their price target on shares of Intellia Therapeutics from $60.00 to $50.00 and set an “overweight” rating on the stock in a research report on Friday, February 28th. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $37.56.

Intellia Therapeutics Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.